Advertisement

A Phase 3 clinical study of a type 1 diabetes treatment by Cambridge biotech Tolerx Inc., in conjunction with British pharmaceutical giant GlaxoSmithKline, failed to meet its primary endpoint.

The study evaluated otelixizumab, a monoclonal antibody drug target, for which the companies had set a primary endpoint goal of seeing a change in C-peptide after a year in patients with type 1 diabetes.

SOURCE

Advertisement
Advertisement